Search
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. … Its structure contains a boron atom, which facilitates skin penetration and binding to the bimetal center of the phosphodiesterase 4 enzyme.
Lebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigational[A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 … Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab].
Dolutegravir
go.drugbank.com/drugs/DB08930ApprovedInvestigational[A31342] Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013. … [A7514] The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity.
Coenzyme M
go.drugbank.com/drugs/DB09110ApprovedInvestigationalCoenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.[A18572]
Prochlorperazine
go.drugbank.com/drugs/DB00433ApprovedInvestigationalVet approved[label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors. … [L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956.
Berahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalBerahyaluronidase alfa is a recombinant variant of human hyaluronidase designed to enhance dispersion and permeation of subcutaneously co-administered drugs. … This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications
Bisoprolol
go.drugbank.com/drugs/DB00612ApprovedInvestigationalBisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure. … [A180472] Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalVIII, but does not contain the B-domain, which has no known biological function, and [DB13192], which is purified endogenous Factor VIII from human pooled blood and contains both A- and B-subunits. … Other drug products with similar structure and function to Efmoroctocog alfa include [DB13999], which is produced by recombinant DNA technology and is identical in sequence to endogenously produced Factor
Betamethasone
go.drugbank.com/drugs/DB00443ApprovedInvestigationalVet approved[A192444] It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders.
Mixtures: FITODERM TC, ACELER-COProducts: BETADERM T (BETAMETASONA0.05 % CREMA)Indomethacin
go.drugbank.com/drugs/DB00328ApprovedInvestigationalIntravenous indometacin is administered to close a hemodynamically significant patent ductus arteriosus, as indicated by clinical evidence, in premature infants. … [A177871] The pharmacological effect of indometacin is not fully understood, however, it is thought to be mediated through potent and nonselective inhibition of the enzyme cyclooxygenase (COX), which is